Skip to main content

Table 4 Relation between HCC recurrence and different parameters in group I

From: Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma recurrence

 

HCC recurrence

Test of Sig.

p

No (n = 31), no. (%)

Yes (n = 19), no. (%)

BCLC

 0

5 (16.1%)

0 (0.0%)

χ2 = 0.161*

0.004*

 A

21 (67.7%)

8 (42.1%)

 B

5 (16.1%)

11 (57.9%)

HCC treatment

 Hepatic resection

5 (16.1%)

6 (31.5%)

χ2 = 4.989*

p = 0.035*

 RFA

16 (51.6%)

11 (57.8%)

χ2 = 0.693

p = 0.405

 LDLT

8 (25.8%)

2 (10.5%)

χ2 = 5.837*

p = 0.018*

 Alcohol injection

2 (6.4%)

0 (0.0%)

χ2 = 0.625

p = 1.000

HCV treatment (weeks)

 Min.–Max.

12.0–24.0

12.0–24.0

t = 1.202

0.238

 Mean ± SD

13.94 ± 4.49

15.79 ± 5.73

 Median

12.0

12.0

HCV treatment

 SOF/DAC

1 (3.2%)

0 (0.0%)

χ2 = 0.625

p = 1.000

 SOF/DAC/RBV

17 (54.8%)

13 (68.4%)

χ2 = 0.905

p = 0.341

 SOF/LED

3 (9.7%)

2 (10.5%)

χ2 = 0.009

p = 1.000

 SOF/LED/RBV

0 (0.0%)

1 (5.3%)

χ2 = 1.665

p = 0.380

 SOF/RBV

6 (19.4%)

3 (15.8%)

χ2 = 0.101

p = 1.000

 SOF/SIM

4 (12.9%)

0 (0.0%)

χ2 = 2.665

p = 0.284

PCR after TTT

 SVR

29 (93.5%)

13 (68.4%)

χ2 = 5.534*

p = 0.041*

 Relapser

2 (6.5%)

6 (31.6%)

  1. SOF sofosbuvir, LED ledipasvir, RBV ribavirin, SIM simeprevir, DAC daclatasvir, SVR sustained virological response